Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
C$124.58+1.89(+1.54%)UPDATE 1-Citi employee killed in shooting at Florida office, suspect dead7:10:16 PM ETADI$402.96-16.84(-4.01%)Analog Devices (ADI) Stock Sinks As Market Gains: Here's Why7:01:11 PM ETXOM$169.08-8.42(-4.74%)Polypropylene Market Size to Reach 139.2 Million Tons by 2032 as Asia-Pacific Packaging and Homopolymer Demand Surge, Reports Mordor Intelligence7:00:00 PM ETGOOG$290.00+2.70(+0.94%)Why Alphabet Stock Popped on Wednesday6:53:01 PM ETAAPL$350.50+0.99(+0.28%)Qualcomm: Apple's Exit Is Accelerating, But So Is Its Replacement6:45:31 PM ETQCOM$161.50-11.69(-6.75%)Qualcomm Stock Down 8% Post Earnings Beat: The Market Lost Its Mind6:15:22 PM ETINTC$58.13-2.37(-3.92%)Intel: The Foundry Trap Is Getting Worse5:48:47 PM ETCVX$217.04+0.08(+0.04%)Joe Terranova Says “Inflation Lost” on Election Night. What That Means for Energy Stocks5:07:08 PM ETQCOM$161.50-11.69(-6.75%)Qualcomm's stock falls as twin forces pressure sales5:03:00 PM ETORCL$124.20+0.47(+0.38%)Wednesday's Final Takeaways: CVS Splitting in Two, ORCL Scraps Tencent Deal5:00:33 PM ETORCL$124.20+0.47(+0.38%)Stock Market Today, Nov. 4: Oracle Falls on Canceled $7 Billion Tencent Chip-Leasing Deal5:00:02 PM ETSPCX$134.88-1.04(-0.77%)How Much Is SpaceX's AI Business Really Worth? Here's the Math.4:59:00 PM ETAMZN$265.96-0.07(-0.03%)Stock Market Today, Nov. 4: Amazon Jumps 6% From New Perspective on AWS Growth and AI Strategy Following Election Results4:53:28 PM ETMETA$631.70+1.70(+0.27%)Meta isn't naming its AI models after fruit anymore4:53:20 PM ETAAPL$350.50+0.99(+0.28%)Apple (AAPL)) Price Forecast: Record High Follows Dramatic Reversal4:52:47 PM ETQCOM$161.50-11.69(-6.75%)Qualcomm's Phone Chip Sales Drop 26%: Rapid Earnings Reaction4:50:19 PM ETMCD$279.00-1.22(-0.44%)Stock Market Today, Nov. 4: Dow Surges 3% in Biggest Post-Midterm Rally in 44 Years4:50:01 PM ETORCL$124.20+0.47(+0.38%)Oracle (ORCL) Stock Slides as Market Rises: Facts to Know Before You Trade4:45:02 PM ETMU$789.00-65.93(-7.71%)Micron (MU) Stock Sinks As Market Gains: Here's Why4:45:02 PM ETAVGO$326.00-6.09(-1.83%)Broadcom Inc. (AVGO) Stock Slides as Market Rises: Facts to Know Before You Trade4:45:02 PM ETDELL$369.50-38.76(-9.49%)Dell Technologies (DELL) Stock Drops Despite Market Gains: Important Facts to Note4:45:02 PM ETCOST$1,055.19+8.72(+0.83%)Costco (COST) Rises Higher Than Market: Key Facts4:45:02 PM ETQCOM$161.50-11.69(-6.75%)Why Qualcomm investors aren't celebrating the Q4 earnings beat4:44:20 PM ETHD$354.67-0.77(-0.22%)Here's What Democrats Taking Back the House and Senate Could Mean for Housing Stocks Like Home Depot and Lowe's4:40:29 PM ET

DNTH · NASDAQ

Dianthus Therapeutics, Inc.

$85.81 +3.10 (+3.75%)

Company overview

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103, which is in Phase 1 clinical trials in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$4.8B
Employees
92
Headquarters
New York, NY
Website
dianthustx.com
CEO
Marino Garcia
Listed
June 21, 2018
P/E
-780.09
Dividend yield
0.00%

Company financials

Revenue
$1.3M
Gross profit
$1.3M
Operating income
-$191M
EBITDA
-$187M
Net income
-$11.3M
EPS
-$0.11
Total assets
$1.2B
Total debt
$1.4M
Gross margin
94.31%
Net margin
-847.53%
Earnings yield
-0.13%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

66.8980.1293.36106.60119.84
DNTH 1D NASDAQ O83.21H86.17L81.57C82.70+0.45 (+0.55%)Vol1.53M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
DNTHDianthus Therapeutics, Inc. Stock news Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates Zacks Investment Research
DNTHDianthus Therapeutics, Inc. Press release Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results GlobeNewswire
DNTHDianthus Therapeutics, Inc. Press release Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
DNTHDianthus Therapeutics, Inc. Press release Dianthus Therapeutics to Participate in Five Investor Conferences During November GlobeNewswire
DNTHDianthus Therapeutics, Inc. Press release Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma GlobeNewswire
DNTHDianthus Therapeutics, Inc. Press release Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting GlobeNewswire
DNTHDianthus Therapeutics, Inc. Stock news Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Seeking Alpha
DNTHDianthus Therapeutics, Inc. Press release Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
DNTHDianthus Therapeutics, Inc. Press release Dianthus Therapeutics to Participate in Three Investor Conferences During September GlobeNewswire
DNTHDianthus Therapeutics, Inc. Stock news Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case Seeking Alpha
DNTHDianthus Therapeutics, Inc. Stock news Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates Zacks Investment Research
DNTHDianthus Therapeutics, Inc. Press release Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results GlobeNewswire
DNTHDianthus Therapeutics, Inc. Press release Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases GlobeNewswire
DNTHDianthus Therapeutics, Inc. Stock news Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win Seeking Alpha
DNTHDianthus Therapeutics, Inc. Press release Dianthus Therapeutics to Participate in Two Investor Conferences GlobeNewswire
DNTHDianthus Therapeutics, Inc. Press release Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases GlobeNewswire
DNTHDianthus Therapeutics, Inc. Stock news Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish Fool - Investing News
DNTHDianthus Therapeutics, Inc. Stock news Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally Fool - Investing News
DNTHDianthus Therapeutics, Inc. Stock news Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company Fool - Investing News
DNTHDianthus Therapeutics, Inc. Stock news Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally Fool - Investing News
See more
FAQ

Questions about Dianthus Therapeutics, Inc.

What does Dianthus Therapeutics, Inc. do?
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103, which is in Phase 1 clinical trials in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
What is DNTH's market cap?
Dianthus Therapeutics, Inc. (DNTH) is a listed stock with a live quote. The latest market cap on this page is $4.8B.
Where is Dianthus Therapeutics, Inc. headquartered?
Dianthus Therapeutics, Inc. is headquartered in New York, NY.
How do I get DNTH news from the API?
Call GET /v1/news?tickers=DNTH. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does DNTH news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for DNTH, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the DNTH price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs